Sponsors trialing drugs in the European Union (EU) will be able to continue seeking input from the European Medicines Agency ...

Study finds Bluesky and X users share clinical trial information differently, which could impact recruitment strategies ...

Susanne Michel, vice president, head of HTA methods and evidence planning at Clinigen, and Michael Epstein, vice president, ...

Monthly insights, guidance alerts and blogs from global life sciences law firms, compiled for you in one place.

The legal experts recently discussed the mechanics of direct-to-patient (DTP) and direct-to-employer (DTE) models.

The company has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 ...

Drug studies in Ontario, Canada, can now start in just 45 days through a study review pathway recently introduced by ...

Investor risk aversion was identified as the leading constraint on biotech investment, cited by 64% of respondents. In Europe ...

Prader-Willi syndrome is a rare genetic condition that can present from birth. Its occurrence is around 1 in 15,000, and tens ...

Viatris will acquire all outstanding shares of Pacira's common stock for $36.50 per share, representing an aggregate equity ...

BioXconomy presents the Asia biopharma and healthcare dealmaking highlights for the week ending October 11, 2026.

Pharma industry is navigating its biggest drug pricing compliance overhaul since 2006, as CMS’ 2026 Physician Fee Schedule ...